Expansion Into China's Lower-tier Cities Could Be Growth Driver For Big Pharma
This article was originally published in PharmAsia News
Executive SummarySHANGHAI - China's pharma market is expected to continue to grow in the next five years with a CAGR of 23.2%, which will be backed largely by the expansion of community health centers across tier 2 and tier 3 cities, according to a report issued by consultancy IMS Health
You may also be interested in...
The reforms will slash drug markups and promote the Essential Drug List and traditional Chinese medicine to control medical expenditures.
Asia Spotlight: With Change On The Horizon, Current Business Models In China Are Not Sustainable – So What’s Next?
Health care reforms will turn the China health care market upside now, meaning that pharma companies must prepare for a new sustainable business model.
Latest research deal for Bayer underscores Beijing’s growing importance as a biotech hub.